New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AbbVie Inc.

ABBV

Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.

Revenue
+10.3%
EPS
+2,270.0%
Free cash flow
+9.97%
Total debt
+17.7%

Quarter to September 2026, against a year earlier

288.61 5.10 +1.80%
Market cap
$501.2B
P/E
48.8×
Fwd P/E FY26e
37.6×
Dividend yield
2.44%
F-score
8/9
ROIC
20.2%
Net debt / EBITDA
2.6×
Payout ratio
1.2×

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 20.2% in Q3 FY26, the highest of these four quarters.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE6155.9%−139.6%−208.1%−288.7%
ROIC16.0%16.8%18.1%20.2%

Debt

Net debt is 8.63× a year’s EBITDA.

Net debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Net debt / EBITDA9.5×10.7×7.7×8.6×

Cash cycle, in days

Customers pay in 75 days, inventory is held 112 days and suppliers are paid in 724. Suppliers fund 538 days of working capital.

Cash cycleDays to pay suppliersDays to be paid
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Cash cycle−522−497−482−538
Days to pay suppliers696669662724
Days to be paid75737875

Per share, from Q4 FY25

Since Q4 FY25, per share: free cash flow has grown 5.93%; revenue has grown 7.94%.

Free cash flowRevenue
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Free cash flow1.0×1.1×1.0×1.1×
Revenue1.0×1.0×1.1×1.1×
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

8 5 7 7
ROE
6,155.88% (139.61%) (208.10%) (288.69%)
ROA
3.11% 2.64% 4.61% 7.32%
ROIC
15.96% 16.85% 18.07% 20.23%
Return on Tangible Assets
(48.68%) (124.65%) (288.01%) 3,229.47%
Average Days of Receivables
75.13 72.51 78.37 74.69
Free Cash Flow per Share
10.07 11.29 10.29 10.67
Free Cash Flow
17,816.00 19,980.00 18,210.00 18,872.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026